



I'm not robot



Continue

The Ides of march

Thanks for visiting my fundraising page. This March I'm walking 10,000 steps a day throughout the month to help beat cancer sooner. Help me Walk All Over Cancer and fund life-saving research by sponsoring me. The Ides of March isn't exactly tops when it comes to well-known dates on the calendar, but thanks to a murder in ancient Rome and a play written by William Shakespeare, people are still proclaiming "Beware the Ides of March." This infamous day has become synonymous with betrayal, lost loyalty and unwelcome surprises. So, what is the Ides of March, and should it really make us wary?A Day of Division and DebtAncient Romans, those clever folks who brought us aqueducts and amphitheatrs, also developed the predecessor to our modern calendar. The name they developed for the first day of each month, Kalends, eventually led to the modern word "calendar." Ancient Romans also determined that one day each month would be known as "Ides," a day that often corresponded with religious observances.According to this calendar, the Ides fell on the 13th day of the month, with the exception of October, July, May and March, when the Ides occurred on the 15th. It was the Ides of March that became a real stickler; it presented a deadline on which citizens were expected to settle all of their debts. It became a day of celebration for those who received payment and a day of woe for those who paid. For some, it was probably both.The concept of Ides was closely tied to the way the people of ancient Rome tracked the passage of time. The Latin roots of "ide" mean "to divide," and in keeping with this sentiment, the Ides took place about midway through each month. The Ides also corresponded with the rise of the full moon. This worked well for a while, as the lunar cycle and the calendar months matched up as expected. Eventually, however, this notion of tracking time based on lunar events created a mismatch between the calendar dates and the full moon.A solution was presented in about 45 B.C.E., when days were added or removed so the calendar would stay in sync with astronomical seasons, such as solstices and equinoxes. The resulting Julian calendar, named posthumously for the military general and politician Julius Caesar who declared himself ruler of the Roman Republic in 43 B.C.E., was based on Earth's revolutions around the sun. It was a 365-day year divided into 12 months with an additional day added every four years to resync the calendar — an event now known as a Leap Year."What is interesting is that the change came about after Caesar had spent some time in Egypt, specifically in the city of Alexandria," says Kelly-Anne Diamond, Ph.D., a visiting assistant professor in the history department at Villanova University, in an email. "The Egyptians had developed previously a calendar of 365 days. However, they did not add that extra 1/4 day, so the Egyptian calendar drifted one day every four years."Through ancient writings, including those of the philosopher Plutarch, it was recorded that Caesar sought help from expert mathematicians — such as the astronomer Sosigenes of Alexandria — in adjusting the calendar."This is important to note, because ancient Egypt does not always receive the credit it deserves as part of the foundation of western culture," Diamond says. "Usually the story begins and ends with Julius Caesar, and relegated to the footnotes is the fact that the Egyptians were technologically savvy and passed on their wisdom to the Roman world."For a time, this Julian calendar seemed to propose an ideal solution — until people realized that an extra day every four years was too many, and a modified Gregorian calendar was developed in 1582. The Gregorian calendar is now used as the official civilian time-tracker in most parts of the world. Even so, the Ides of March from the Julian calendar are still part of our collective consciousness, thanks in large part to Caesar's untimely death and a Shakespeare play that immortalized it. Since Caesar's assassination, the middle of March has become synonymous with bad tidings, unwelcome omens and disaster.A Day to BewareIn 44 B.C.E., about one year into Julius Caesar's rule of Rome, things seemed to be going well. Caesar had a number of military victories under his belt after taking over parts of Belgium, France, Germany, Spain and Switzerland, and he was generally quite popular among his constituents. Caesar had appointed several political leaders that comprised Rome's senate, but tensions were building. Members of the Senate worried that with Caesar's mounting popularity and his recent self-appointment of "dictator in perpetuity" would lead to a disastrous political outcome for Rome. Members of the Senate feared Caesar would disband the Senate and rule of his own accord without their input.The brewing opposition to Caesar's rule came to a head on the Ides of March — March 15 — in 44 B.C.E. when about 40 Roman senators stabbed Caesar to death as the group was on its way to a sporting event at the Theatre of Pompey in Rome. The conspiracy, led by Gaius Cassius Longinus and Marcus Junius Brutus, was kept under wraps by the dozens of senators involved."Julius Caesar ... managed to anger enough people that he was taken out by his own Senate for the greater good," says Kate Wiswell, historical hobbyist and author, in an email interview. "Sadly, his removal did not usher in the revolution people had hoped for, because they fought so much about how to replace him that they ended up with yet another empirical Caesar just like him."After a period of public outrage and a series of civil wars, Caesar's nephew Octavian began calling himself Caesar Augustus and claimed rule of what would become the Roman Empire, ending ancient Rome's brush with a government ruled by representatives of the people. While this month's security updates weren't released exactly on the Ides of March, they certainly caused disruption for many users. (For those not into history or Shakespeare, the Ides of March — March 15, 44 BC — is famous as the day Julius Caesar was assassinated.) Microsoft's March 9 patch release brought more bumpsiness and issues than a 1 can remember in a long time. Perhaps we should reassign the date for this year's Ides of March to March 9 as an unofficial acknowledgment.As I alluded to last week, this month was bumpy in terms of patching side effects. Here's what we know: The March updates included fixes for printing that triggered blue screens of death on computers when users tried to print. In the case of Dymo label printers (and other bar code or graphical printers) they left them printing out blank labels. Larger business-style multifunction printers saw issues, especially where you have an older PCL 3 or PCL 4 style driver. Ricoh and Kyocera users reported the most issues. (One workaround: use a generic PCL 6 driver instead, though you might lose some functions.) Any Kyocera printers that use the XX driver are affected, as are some Okidata, NiceLabel, and point-of-sale system printers from applications called BarTender. For many, the Dymo label printer issue is the worst. I have HP, Brother, and Lexmark printers and have not seen issues with the March 9 base security updates for Windows 10, 8.1, or Windows 7. First, I recommend installing the updates released on the Patch Tuesday and, once you try system restores, testing your printing functions. If you run into problems, you have two choices:Option 1: Uninstall the update and pause the installation of updates until April. For those running Windows 10, click on Start, Settings, Update and security, Click on View update history, Click on uninstall update, find the KB and click. The system will uninstall the update and roll itself back to the February patches. Now pause updates by clicking on Start, Settings, Update and security, Windows update, Advanced options and Pick a new date. You can view a video of this process on the Askwocky channel.Option 2: Pick the latest (March 18) updates and install those. There are two ways to find the right one for your system: The optional update should be offered to you if you go to the Windows update section of your computer; if it isn't, you can also go to the catalog site. I go to the Windows 10 update history site, and find version of Windows I am running, then I look for the patches dated March 18 to find the patch number I need, then go to the catalog site and search it. Then you can click on the link offered up and install it. Reboot and see if printing works. If not, uninstall the update (as noted above) and pause until April. Note: since Windows 10 updates are cumulative, you need only install the latest March 18 release, not the one from March 15.For Windows 10 20H2 you should skip the March 9 updates and jump over to the March 18 update for KB5001649. It should be offered up to you as an optional update, or you can download it from the catalog site. (For Windows 10 1909, you need KB5001648; it would also be offered up as an optional update if you go to the Windows update interface or you can download it from the catalog site.)It appears that the underlying issues triggered by these updates are caused by Microsoft attempting to fix a privilege escalation bug. As noted in the bulletins: "Addresses an elevation of privilege security vulnerability documented in CVE-2021-1646 related to print jobs submitted to "FILE:" ports. After installing Windows updates on March 9, 2021 and later, print jobs that are in a pending state before restarting the print spooler service or restarting the OS will remain in an error state. Manually delete the affected print jobs and resubmit them to the print queue when the print spooler service is online."Last June, Microsoft fixed a similar issue and I had issues printing to my Ricoh printers. Back then there were no "fixing" patches; I had to redeforeprint drivers and share them back out to all of the workstations. In a business setting, this process is cumbersome and disruptive and I often find myself having to go back and tweak settings that I had forgotten such as turning off dual-sided printing (which we don't use as a default in my firm). If you were affected by these updates, I would take this as a sign that you need to find a newer printer driver from your vendor. Like the mandatory updates for video drivers that Windows 10 demands, printers can be an entry-point for attackers. Elevation-of-privilege bugs are not as critical as remote-code attacks, but when attackers can send out phishing emails and trick you to click on something, or when zero-day browser vulnerabilities can be bundled with these bugs, it's important to deal with them.I look for new printer drivers by going to the vendor's site and putting in the version number of the printer I use. I then look for the exact model and try to find a driver that is simply a printer driver and does not include notifications that my print cartridges are low, or any other software that may slow down my system. Look for a driver date in the last few years, if you can. (If your printer is older, you may have to install a generic driver rather than the one from the manufacturer.) If you take time now to review what printer driver you have, and update accordingly, you'll be safer and less likely to run into patching issues in the future.Microsoft did not make this March patching season easy. Let's hope April brings us a nice, quiet, headline-free patch day. As always, join us on Askwoody if you need more help or guidance installing updates. Copyright © 2021 IDG Communications, Inc. De Agostini / L. RomanoGetty Images If you think the expression "Beware the Ides of March" sounds slightly ominous, you're not alone. The phrase is best known for appearing in the text of the William Shakespeare tragedy Julius Caesar, where it hints at the eventual assassination of the Roman dictator. When a fortune teller cautions him, "Beware the Ides of March," Caesar makes light of the warning, eventually paying the ultimate price. However, barring Caesar's misfortune there is no inherently sinister meaning behind the expression. It's simply a date on the Roman calendar. The ancient culture didn't number days from first to last for each month. Instead, they kept track of time using three fixed dates: The Kalends at the month's start, followed by the Nones around the 7th, and the Ides, intended to occur the day of the full moon, in the middle of the month. The other days were counted as a group before the next named day. For example, in March the Ides falls on the 15th; days 8 to 14 were simply referred to as before the Ides. While not inauspicious, the Ides of March was still of note to the Romans—several religious festivals were held on the date, and it was used as a deadline for settling debts as well. De Agostini Picture Library/Getty Images And just as in Shakespeare's play, it was the actual day in 44 B.C. the real-life Caesar was assassinated. According to the Greek biographer and essayist Plutarch, Caesar really was instructed to beware the Ides of March by a soothsayer. Instead, he continued on to a meeting with the Roman Senate, where he was stabbed to death by 60 conspirators. Their intent was to halt his quest for power and restore the Roman Republic, but instead the country was plunged into civil war. Eventually, Octavian, Caesar's grand-nephew and adopted heir, would rise from the chaos as Augustus, the first emperor of Rome. The republic was forever lost. jla66/Getty Images There are other infamous events that have occurred on March 15th, from Czar Nicholas II abdicating the Russian throne in 1917—which led to the firing squad deaths of him and his entire family a year later—to Nazi troops seizing control of Czechoslovakia in 1939. But thanks to a little help from the world's most famous playwright, no other single incident has doomed March 15th to its baleful reputation quite like Julius Caesar's assassination. This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io This site is not available in your country A sponsor of a significant risk device study must submit a complete IDE application to FDA. There are no preprinted forms for an IDE application; however, an IDE application must include certain required information. The sponsor must demonstrate in the application that there is reason to believe that the risks to human subjects from the proposed investigation are outweighed by the anticipated benefits to subjects and the importance of the knowledge to be gained, that the investigation is scientifically sound, and that there is reason to believe that the device as proposed for use will be effective. Required Elements The following information must be included in an IDE application for a significant risk device investigation. A sponsor cannot begin a significant risk device investigation until FDA and IRB approval are granted. A valid eCopy is typically required and the application must include the following in the order provided (§ 812.20): Name and address of sponsor Report of prior investigations (§ 812.27). A report of prior investigations must include reports of all prior clinical, animal, and laboratory testing of the device. It should be comprehensive and adequate to justify the proposed investigation. Specific contents of the report must include: a bibliography of all publications, whether adverse or supportive, that are relevant to an evaluation of the safety and effectiveness of the device copies of all published and unpublished adverse information copies of other significant publications if requested by an IRB or FDA a summary of all other unpublished information (whether adverse or supportive) that is relevant to an evaluation of the safety and effectiveness of the device if nonclinical laboratory data are provided, a statement that such studies have been conducted in compliance with the Good Laboratory Practice (GLP) regulations in 21 CFR Part 58. If the study was not conducted in compliance with the GLP regulations, include a brief statement of the reason for noncompliance. Investigational plan (§812.25) The investigational plan shall include the following items in the following order: purpose (the name and intended use of the device and the objectives and duration of the investigation) protocol (a written protocol describing the methodology to be used and an analysis of the protocol demonstrating its scientific soundness) risk analysis (an analysis of all increased risks to the research subjects and how these risks will be minimized; a justification for the investigation; and a description of the patient population including the number, age, sex, and condition) description of this device (a description of each important component, ingredient, property, and principle of operation of the device and any anticipated changes in the device during the investigation) monitoring procedures (the sponsor's written procedures for monitoring the investigation and the name and address of each monitor; additional records and reports (a description of any records or reports of the investigation other than those required in Subpart G of the IDE regulations). A description of the methods, facilities, and controls used for the manufacture, processing, packing, storage, and installation of the device An example of the agreement to be signed by the investigators and a list of the names and addresses of all investigators. Information that must be included in the written agreement are found in § 812.43 Certification that all investigators have signed the agreement, that the list of investigators includes all investigators participating in the study, and that new investigators will sign the agreement before being added to the study A list of the names, addresses, and chairpersons of all IRBs that have or will be asked to review the investigation and a certification of IRB action concerning the investigation (when available) The name and address of any institution (other than those above) where a part of the investigation may be conducted The amount, if any, charged for the device and an explanation of why sale does not constitute commercialization Yes/No § 810(b)(7) prohibits the commercialization of an investigational device by charging subjects or investigators for a device a price larger than necessary to recover costs of manufacture, research, development, and handling. Environmental Impact Assessment: (§812.20(b)(9)) An environmental impact assessment or a claim for categorical exclusion is no longer required. (§25.34(g)) Labeling: (§812.5) Are copies of all labeling for the device provided and include the following? Does the labeling contain the statement "CAUTION- Investigational Device. Limited by Federal (or United States) Law to Investigational Use." § 812.3(a)(1)) Yes/No Does the labeling contain adequate information for the purposes of the investigation, in accordance with § 812.3(a), including the name and place of business of the manufacturer, packer, or distributor, the quantity of contents, and a statement of the investigator's intent to: conduct the investigation in accordance with the agreement, the investigational plan, Part 812 and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB and FDA, supervise all testing of the device involving human subjects, and ensure that the requirements for obtaining informed consent are met Investigator's commitment to provide sufficient and accurate financial disclosure information and update information if any relevant changes occur during the investigation and for one year following the completion of the study. Yes/No Certification that all participating investigators have signed the agreement and that no investigator will be added until the agreement is signed. §812.20(b)(5) Yes/No Name and address of investigators who have signed the agreement. Yes/No IRB information: Are the following items included? Name, address, and chairperson of each IRB Yes/No Certification of the action taken by each IRB. (i.e., approval letter) How many IRBs have approved the investigation? How many IRBs are currently reviewing the investigation or will review it in the future? Yes/No Names and addresses of any institutions (other than those identified above) where a part of the investigation may be conducted Yes/No Sales Information: (§12.7(b)) Is the following information provided? Is the device to be sold? Yes/No If yes, is the amount to be charged provided? Yes/No Explanation of why sale does not constitute commercialization Yes/No § 812.7(b) prohibits the commercialization of an investigational device by charging subjects or investigators for a device a price larger than necessary to recover costs of manufacture, research, development, and handling. Environmental Impact Assessment: (§812.20(b)(9)) An environmental impact assessment or a claim for categorical exclusion is no longer required. (§25.34(g)) Labeling: (§812.5) Are copies of all labeling for the device provided and include the following? Does the labeling contain the statement "CAUTION- Investigational Device. Limited by Federal (or United States) Law to Investigational Use." § 812.3(a)(1)) Yes/No Does the labeling contain adequate information for the purposes of the investigation, in accordance with § 812.3(a), including the name and place of business of the manufacturer, packer, or distributor, the quantity of contents, and a statement of the investigator's intent to: conduct the investigation in accordance with the agreement, the investigational plan, Part 812 and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB and FDA, supervise all testing of the device involving human subjects, and ensure that the requirements for obtaining informed consent are met Investigator's commitment to provide sufficient and accurate financial disclosure information and update information if any relevant changes occur during the investigation and for one year following the completion of the study. Yes/No Certification that all participating investigators have signed the agreement and that no investigator will be added until the agreement is signed. §812.20(b)(5) Yes/No Name and address of investigators who have signed the agreement. Yes/No IRB information: Are the following items included? Name, address, and chairperson of each IRB Yes/No Certification of the action taken by each IRB. (i.e., approval letter) How many IRBs have approved the investigation? How many IRBs are currently reviewing the investigation or will review it in the future? Yes/No Names and addresses of any institutions (other than those identified above) where a part of the investigation may be conducted Yes/No Sales Information: (§12.7(b)) Is the following information provided? Is the device to be sold? Yes/No If yes, is the amount to be charged provided? Yes/No Explanation of why sale does not constitute commercialization Yes/No § 812.7(b) prohibits the commercialization of an investigational device by charging subjects or investigators for a device a price larger than necessary to recover costs of manufacture, research, development, and handling. Environmental Impact Assessment: (§812.20(b)(9)) An environmental impact assessment or a claim for categorical exclusion is no longer required. (§25.34(g)) Labeling: (§812.5) Are copies of all labeling for the device provided and include the following? Does the labeling contain the statement "CAUTION- Investigational Device. Limited by Federal (or United States) Law to Investigational Use." § 812.3(a)(1)) Yes/No Does the labeling contain adequate information for the purposes of the investigation, in accordance with § 812.3(a), including the name and place of business of the manufacturer, packer, or distributor, the quantity of contents, and a statement of the investigator's intent to: conduct the investigation in accordance with the agreement, the investigational plan, Part 812 and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB and FDA, supervise all testing of the device involving human subjects, and ensure that the requirements for obtaining informed consent are met Investigator's commitment to provide sufficient and accurate financial disclosure information and update information if any relevant changes occur during the investigation and for one year following the completion of the study. Yes/No Certification that all participating investigators have signed the agreement and that no investigator will be added until the agreement is signed. §812.20(b)(5) Yes/No Name and address of investigators who have signed the agreement. Yes/No IRB information: Are the following items included? Name, address, and chairperson of each IRB Yes/No Certification of the action taken by each IRB. (i.e., approval letter) How many IRBs have approved the investigation? How many IRBs are currently reviewing the investigation or will review it in the future? Yes/No Names and addresses of any institutions (other than those identified above) where a part of the investigation may be conducted Yes/No Sales Information: (§12.7(b)) Is the following information provided? Is the device to be sold? Yes/No If yes, is the amount to be charged provided? Yes/No Explanation of why sale does not constitute commercialization Yes/No § 812.7(b) prohibits the commercialization of an investigational device by charging subjects or investigators for a device a price larger than necessary to recover costs of manufacture, research, development, and handling. Environmental Impact Assessment: (§812.20(b)(9)) An environmental impact assessment or a claim for categorical exclusion is no longer required. (§25.34(g)) Labeling: (§812.5) Are copies of all labeling for the device provided and include the following? Does the labeling contain the statement "CAUTION- Investigational Device. Limited by Federal (or United States) Law to Investigational Use." § 812.3(a)(1)) Yes/No Does the labeling contain adequate information for the purposes of the investigation, in accordance with § 812.3(a), including the name and place of business of the manufacturer, packer, or distributor, the quantity of contents, and a statement of the investigator's intent to: conduct the investigation in accordance with the agreement, the investigational plan, Part 812 and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB and FDA, supervise all testing of the device involving human subjects, and ensure that the requirements for obtaining informed consent are met Investigator's commitment to provide sufficient and accurate financial disclosure information and update information if any relevant changes occur during the investigation and for one year following the completion of the study. Yes/No Certification that all participating investigators have signed the agreement and that no investigator will be added until the agreement is signed. §812.20(b)(5) Yes/No Name and address of investigators who have signed the agreement. Yes/No IRB information: Are the following items included? Name, address, and chairperson of each IRB Yes/No Certification of the action taken by each IRB. (i.e., approval letter) How many IRBs have approved the investigation? How many IRBs are currently reviewing the investigation or will review it in the future? Yes/No Names and addresses of any institutions (other than those identified above) where a part of the investigation may be conducted Yes/No Sales Information: (§12.7(b)) Is the following information provided? Is the device to be sold? Yes/No If yes, is the amount to be charged provided? Yes/No Explanation of why sale does not constitute commercialization Yes/No § 812.7(b) prohibits the commercialization of an investigational device by charging subjects or investigators for a device a price larger than necessary to recover costs of manufacture, research, development, and handling. Environmental Impact Assessment: (§812.20(b)(9)) An environmental impact assessment or a claim for categorical exclusion is no longer required. (§25.34(g)) Labeling: (§812.5) Are copies of all labeling for the device provided and include the following? Does the labeling contain the statement "CAUTION- Investigational Device. Limited by Federal (or United States) Law to Investigational Use." § 812.3(a)(1)) Yes/No Does the labeling contain adequate information for the purposes of the investigation, in accordance with § 812.3(a), including the name and place of business of the manufacturer, packer, or distributor, the quantity of contents, and a statement of the investigator's intent to: conduct the investigation in accordance with the agreement, the investigational plan, Part 812 and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB and FDA, supervise all testing of the device involving human subjects, and ensure that the requirements for obtaining informed consent are met Investigator's commitment to provide sufficient and accurate financial disclosure information and update information if any relevant changes occur during the investigation and for one year following the completion of the study. Yes/No Certification that all participating investigators have signed the agreement and that no investigator will be added until the agreement is signed. §812.20(b)(5) Yes/No Name and address of investigators who have signed the agreement. Yes/No IRB information: Are the following items included? Name, address, and chairperson of each IRB Yes/No Certification of the action taken by each IRB. (i.e., approval letter) How many IRBs have approved the investigation? How many IRBs are currently reviewing the investigation or will review it in the future? Yes/No Names and addresses of any institutions (other than those identified above) where a part of the investigation may be conducted Yes/No Sales Information: (§12.7(b)) Is the following information provided? Is the device to be sold? Yes/No If yes, is the amount to be charged provided? Yes/No Explanation of why sale does not constitute commercialization Yes/No § 812.7(b) prohibits the commercialization of an investigational device by charging subjects or investigators for a device a price larger than necessary to recover costs of manufacture, research, development, and handling. Environmental Impact Assessment: (§812.20(b)(9)) An environmental impact assessment or a claim for categorical exclusion is no longer required. (§25.34(g)) Labeling: (§812.5) Are copies of all labeling for the device provided and include the following? Does the labeling contain the statement "CAUTION- Investigational Device. Limited by Federal (or United States) Law to Investigational Use." § 812.3(a)(1)) Yes/No Does the labeling contain adequate information for the purposes of the investigation, in accordance with § 812.3(a), including the name and place of business of the manufacturer, packer, or distributor, the quantity of contents, and a statement of the investigator's intent to: conduct the investigation in accordance with the agreement, the investigational plan, Part 812 and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB and FDA, supervise all testing of the device involving human subjects, and ensure that the requirements for obtaining informed consent are met Investigator's commitment to provide sufficient and accurate financial disclosure information and update information if any relevant changes occur during the investigation and for one year following the completion of the study. Yes/No Certification that all participating investigators have signed the agreement and that no investigator will be added until the agreement is signed. §812.20(b)(5) Yes/No Name and address of investigators who have signed the agreement. Yes/No IRB information: Are the following items included? Name, address, and chairperson of each IRB Yes/No Certification of the action taken by each IRB. (i.e., approval letter) How many IRBs have approved the investigation? How many IRBs are currently reviewing the investigation or will review it in the future? Yes/No Names and addresses of any institutions (other than those identified above) where a part of the investigation may be conducted Yes/No Sales Information: (§12.7(b)) Is the following information provided? Is the device to be sold? Yes/No If yes, is the amount to be charged provided? Yes/No Explanation of why sale does not constitute commercialization Yes/No § 812.7(b) prohibits the commercialization of an investigational device by charging subjects or investigators for a device a price larger than necessary to recover costs of manufacture, research, development, and handling. Environmental Impact Assessment: (§812.20(b)(9)) An environmental impact assessment or a claim for categorical exclusion is no longer required. (§25.34(g)) Labeling: (§812.5) Are copies of all labeling for the device provided and include the following? Does the labeling contain the statement "CAUTION- Investigational Device. Limited by Federal (or United States) Law to Investigational Use." § 812.3(a)(1)) Yes/No Does the labeling contain adequate information for the purposes of the investigation, in accordance with § 812.3(a), including the name and place of business of the manufacturer, packer, or distributor, the quantity of contents, and a statement of the investigator's intent to: conduct the investigation in accordance with the agreement, the investigational plan, Part 812 and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB and FDA, supervise all testing of the device involving human subjects, and ensure that the requirements for obtaining informed consent are met Investigator's commitment to provide sufficient and accurate financial disclosure information and update information if any relevant changes occur during the investigation and for one year following the completion of the study. Yes/No Certification that all participating investigators have signed the agreement and that no investigator will be added until the agreement is signed. §812.20(b)(5) Yes/No Name and address of investigators who have signed the agreement. Yes/No IRB information: Are the following items included? Name, address, and chairperson of each IRB Yes/No Certification of the action taken by each IRB. (i.e., approval letter) How many IRBs have approved the investigation? How many IRBs are currently reviewing the investigation or will review it in the future? Yes/No Names and addresses of any institutions (other than those identified above) where a part of the investigation may be conducted Yes/No Sales Information: (§12.7(b)) Is the following information provided? Is the device to be sold? Yes/No If yes, is the amount to be charged provided? Yes/No Explanation of why sale does not constitute commercialization Yes/No § 812.7(b) prohibits the commercialization of an investigational device by charging subjects or investigators for a device a price larger than necessary to recover costs of manufacture, research, development, and handling. Environmental Impact Assessment: (§812.20(b)(9)) An environmental impact assessment or a claim for categorical exclusion is no longer required. (§25.34(g)) Labeling: (§812.5) Are copies of all labeling for the device provided and include the following? Does the labeling contain the statement "CAUTION- Investigational Device. Limited by Federal (or United States) Law to Investigational Use." § 812.3(a)(1)) Yes/No Does the labeling contain adequate information for the purposes of the investigation, in accordance with § 812.3(a), including the name and place of business of the manufacturer, packer, or distributor, the quantity of contents, and a statement of the investigator's intent to: conduct the investigation in accordance with the agreement, the investigational plan, Part 812 and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB and FDA, supervise all testing of the device involving human subjects, and ensure that the requirements for obtaining informed consent are met Investigator's commitment to provide sufficient and accurate financial disclosure information and update information if any relevant changes occur during the investigation and for one year following the completion of the study. Yes/No Certification that all participating investigators have signed the agreement and that no investigator will be added until the agreement is signed. §812.20(b)(5) Yes/No Name and address of investigators who have signed the agreement. Yes/No IRB information: Are the following items included? Name, address, and chairperson of each IRB Yes/No Certification of the action taken by each IRB. (i.e., approval letter) How many IRBs have approved the investigation? How many IRBs are currently reviewing the investigation or will review it in the future? Yes/No Names and addresses of any institutions (other than those identified above) where a part of the investigation may be conducted Yes/No Sales Information: (§12.7(b)) Is the following information provided? Is the device to be sold? Yes/No If yes, is the amount to be charged provided? Yes/No Explanation of why sale does not constitute commercialization Yes/No § 812.7(b) prohibits the commercialization of an investigational device by charging subjects or investigators for a device a price larger than necessary to recover costs of manufacture, research, development, and handling. Environmental Impact Assessment: (§812.20(b)(9)) An environmental impact assessment or a claim for categorical exclusion is no longer required. (§25.34(g)) Labeling: (§812.5) Are copies of all labeling for the device provided and include the following? Does the labeling contain the statement "CAUTION- Investigational Device. Limited by Federal (or United States) Law to Investigational Use." § 812.3(a)(1)) Yes/No Does the labeling contain adequate information for the purposes of the investigation, in accordance with § 812.3(a), including the name and place of business of the manufacturer, packer, or distributor, the quantity of contents, and a statement of the investigator's intent to: conduct the investigation in accordance with the agreement, the investigational plan, Part 812 and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB and FDA, supervise all testing of the device involving human subjects, and ensure that the requirements for obtaining informed consent are met Investigator's commitment to provide sufficient and accurate financial disclosure information and update information if any relevant changes occur during the investigation and for one year following the completion of the study. Yes/No Certification that all participating investigators have signed the agreement and that no investigator will be added until the agreement is signed. §812.20(b)(5) Yes/No Name and address of investigators who have signed the agreement. Yes/No IRB information: Are the following items included? Name, address, and chairperson of each IRB Yes/No Certification of the action taken by each IRB. (i.e., approval letter) How many IRBs have approved the investigation? How many IRBs are currently reviewing the investigation or will review it in the future? Yes/No Names and addresses of any institutions (other than those identified above) where a part of the investigation may be conducted Yes/No Sales Information: (§12.7(b)) Is the following information provided? Is the device to be sold? Yes/No If yes, is the amount to be charged provided? Yes/No Explanation of why sale does not constitute commercialization Yes/No § 812.7(b) prohibits the commercialization of an investigational device by charging subjects or investigators for a device a price larger than necessary to recover costs of manufacture, research, development, and handling. Environmental Impact Assessment: (§812.20(b)(9)) An environmental impact assessment or a claim for categorical exclusion is no longer required. (§25.34(g)) Labeling: (§812.5) Are copies of all labeling for the device provided and include the following? Does the labeling contain the statement "CAUTION- Investigational Device. Limited by Federal (or United States) Law to Investigational Use." § 812.3(a)(1)) Yes/No Does the labeling contain adequate information for the purposes of the investigation, in accordance with § 812.3(a), including the name and place of business of the manufacturer, packer, or distributor, the quantity of contents, and a statement of the investigator's intent to: conduct the investigation in accordance with the agreement, the investigational plan, Part 812 and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB and FDA, supervise all testing of the device involving human subjects, and ensure that the requirements for obtaining informed consent are met Investigator's commitment to provide sufficient and accurate financial disclosure information and update information if any relevant changes occur during the investigation and for one year following the completion of the study. Yes/No Certification that all participating investigators have signed the agreement and that no investigator will be added until the agreement is signed. §812.20(b)(5) Yes/No Name and address of investigators who have signed the agreement. Yes/No IRB information: Are the following items included? Name, address, and chairperson of each IRB Yes/No Certification of the action taken by each IRB. (i.e., approval letter) How many IRBs have approved the investigation? How many IRBs are currently reviewing the investigation or will review it in the future? Yes/No Names and addresses of any institutions (other than those identified above) where a part of the investigation may be conducted Yes/No Sales Information: (§12.7(b)) Is the following information provided? Is the device to be sold? Yes/No If yes, is the amount to be charged provided? Yes/No Explanation of why sale does not constitute commercialization Yes/No § 812.7(b) prohibits the commercialization of an investigational device by charging subjects or investigators for a device a price larger than necessary to recover costs of manufacture, research, development, and handling. Environmental Impact Assessment: (§812.20(b)(9)) An environmental impact assessment or a claim for categorical exclusion is no longer required. (§25.34(g)) Labeling: (§812.5) Are copies of all labeling for the device provided and include the following? Does the labeling contain the statement "CAUTION- Investigational Device. Limited by Federal (or United States) Law to Investigational Use." § 812.3(a)(1)) Yes/No Does the labeling contain adequate information for the purposes of the investigation, in accordance with § 812.3(a), including the name and place of business of the manufacturer, packer, or distributor, the quantity of contents, and a statement of the investigator's intent to: conduct the investigation in accordance with the agreement, the investigational plan, Part 812 and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB and FDA, supervise all testing of the device involving human subjects, and ensure that the requirements for obtaining informed consent are met Investigator's commitment to provide sufficient and accurate financial disclosure information and update information if any relevant changes occur during the investigation and for one year following the completion of the study. Yes/No Certification that all participating investigators have signed the agreement and that no investigator will be added until the agreement is signed. §812.20(b)(5) Yes/No Name and address of investigators who have signed the agreement. Yes/No IRB information: Are the following items included? Name, address, and chairperson of each IRB Yes/No Certification of the action taken by each IRB. (i.e., approval letter) How many IRBs have approved the investigation? How many IRBs are currently reviewing the investigation or will review it in the future? Yes/No Names and addresses of any institutions (other than those identified above) where a part of the investigation may be conducted Yes/No Sales Information: (§12.7(b)) Is the following information provided? Is the device to be sold? Yes/No If yes, is the amount to be charged provided? Yes/No Explanation of why sale does not constitute commercialization Yes/No § 812.7(b) prohibits the commercialization of an investigational device by charging subjects or investigators for a device a price larger than necessary to recover costs of manufacture, research, development, and handling. Environmental Impact Assessment: (§812.20(b)(9)) An environmental impact assessment or a claim for categorical exclusion is no longer required. (§25.34(g)) Labeling: (§812.5) Are copies of all labeling for the device provided and include the following? Does the labeling contain the statement "CAUTION- Investigational Device. Limited by Federal (or United States) Law to Investigational Use." § 812.3(a)(1)) Yes/No Does the labeling contain adequate information for the purposes of the investigation, in accordance with § 812.3(a), including the name and place of business of the manufacturer, packer, or distributor, the quantity of contents, and a statement of the investigator's intent to: conduct the investigation in accordance with the agreement, the investigational plan, Part 812 and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB and FDA, supervise all testing of the device involving human subjects, and ensure that the requirements for obtaining informed consent are met Investigator's commitment to provide sufficient and accurate financial disclosure information and update information if any relevant changes occur during the investigation and for one year following the completion of the study. Yes/No Certification that all participating investigators have signed the agreement and that no investigator will be added until the agreement is signed. §812.20(b)(5) Yes/No Name and address of investigators who have signed the agreement. Yes/No IRB information: Are the following items included? Name, address, and chairperson of each IRB Yes/No Certification of the action taken by each IRB. (i.e., approval letter) How many IRBs have approved the investigation? How many IRBs are currently reviewing the investigation or will review it in the future? Yes/No Names and addresses of any institutions (other than those identified above) where a part of the investigation may be conducted Yes/No Sales Information: (§12.7(b)) Is the following information provided? Is the device to be sold? Yes/No If yes, is the amount to be charged provided? Yes/No Explanation of why sale does not constitute commercialization Yes/No § 812.7(b) prohibits the commercialization of an investigational device by charging subjects or investigators for a device a price larger than necessary to recover costs of manufacture, research, development, and handling. Environmental Impact Assessment: (§812.20(b)(9)) An environmental impact assessment or a claim for categorical exclusion is no longer required. (§25.34(g)) Labeling: (§812.5) Are copies of all labeling for the device provided and include the following? Does the labeling contain the statement "CAUTION- Investigational Device. Limited by Federal (or United States) Law to Investigational Use." § 812.3(a)(1)) Yes/No Does the labeling contain adequate information for the purposes of the investigation, in accordance with § 812.3(a), including the name and place of business of the manufacturer, packer, or distributor, the quantity of contents, and a statement of the investigator's intent to: conduct the investigation in accordance with the agreement, the investigational plan, Part 812 and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB and FDA, supervise all testing of the device involving human subjects, and ensure that the requirements for obtaining informed consent are met Investigator's commitment to provide sufficient and accurate financial disclosure information and update information if any relevant changes occur during the investigation and for one year following the completion of the study. Yes/No Certification that all participating investigators have signed the agreement and that no investigator will be added until the agreement is signed. §812.20(b)(5) Yes/No Name and address of investigators who have signed the agreement. Yes/No IRB information: Are the following items included? Name, address, and chairperson of each IRB Yes/No Certification of the action taken by each IRB. (i.e., approval letter) How many IRBs have approved the investigation? How many IRBs are currently reviewing the investigation or will review it in the future? Yes/No Names and addresses of any institutions (other than those identified above) where a part of the investigation may be conducted Yes/No Sales Information: (§12.7(b)) Is the following information provided? Is the device to be sold? Yes/No If yes, is the amount to be charged provided? Yes/No Explanation of why sale does not constitute commercialization Yes/No § 812.7(b) prohibits the commercialization of an investigational device by charging subjects or investigators for a device a price larger than necessary to recover costs of manufacture, research, development, and handling. Environmental Impact Assessment: (§812.20(b)(9)) An environmental impact assessment or a claim for categorical exclusion is no longer required. (§25.34(g)) Labeling: (§812.5) Are copies of all labeling for the device provided and include the following? Does the labeling contain the statement "CAUTION- Investigational Device. Limited by Federal (or United States) Law to Investigational Use." § 812.3(a)(1)) Yes/No Does the labeling contain adequate information for the purposes of the investigation, in accordance with § 812.3(a), including the name and place of business of the manufacturer, packer, or distributor, the quantity of contents, and a statement of the investigator's intent to: conduct the investigation in accordance with the agreement, the investigational plan, Part 812 and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB and FDA, supervise all testing of the device involving human subjects, and ensure that the requirements for obtaining informed consent are met Investigator's commitment to provide sufficient and accurate financial disclosure information and update information if any relevant changes occur during the investigation and for one year following the completion of the study. Yes/No Certification that all participating investigators have signed the agreement and that no investigator will be added until the agreement is signed. §812.20(b)(5) Yes/No Name and address of investigators who have signed the agreement. Yes/No IRB information: Are the following items included? Name, address, and chairperson of each IRB Yes/No Certification of the action taken by each IRB. (i.e., approval letter) How many IRBs have approved the investigation? How many IRBs are currently reviewing the investigation or will review it in the future? Yes/No Names and addresses of any institutions (other than those identified above) where a part of the investigation may be conducted Yes/No Sales Information: (§12.7(b)) Is the following information provided? Is the device to be sold? Yes/No If yes, is the amount to be charged provided? Yes/No Explanation of why sale does not constitute commercialization Yes/No § 812.7(b) prohibits the commercialization of an investigational device by charging subjects or investigators for a device a price larger than necessary to recover costs of manufacture, research, development, and handling. Environmental Impact Assessment: (§812.20(b)(9)) An environmental impact assessment or a claim for categorical exclusion is no longer required. (§25.34(g)) Labeling: (§812.5) Are copies of all labeling for the device provided and include the following? Does the labeling contain the statement "CAUTION- Investigational Device. Limited by Federal (or United States) Law to Investigational Use." § 812.3(a)(1)) Yes/No Does the labeling contain adequate information for the purposes of the investigation, in accordance with § 812.3(a), including the name and place of business of the manufacturer, packer, or distributor, the quantity of contents, and a statement of the investigator's intent to: conduct the investigation in accordance with the agreement, the investigational plan, Part 812 and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB and FDA, supervise all testing of the device involving human subjects, and ensure that the requirements for obtaining informed consent are met Investigator's commitment to provide sufficient and accurate financial disclosure information and update information if any relevant changes occur during the investigation and for one year following the completion of the study. Yes/No Certification that all participating investigators have signed the agreement and that no investigator will be added until the agreement is signed. §812.20(b)(5) Yes/No Name and address of investigators who have signed the agreement. Yes/No IRB information: Are the following items included? Name, address, and chairperson of each IRB Yes/No Certification of the action taken by each IRB. (i.e., approval letter) How many IRBs have approved the investigation? How many IRBs are currently reviewing the investigation or will review it in the future? Yes/No Names and addresses of any institutions (other than those identified above) where a part of the investigation may be conducted Yes/No Sales Information: (§12.7(b)) Is the following information provided? Is the device to be sold? Yes/No If yes, is the amount to be charged provided? Yes/No Explanation of why sale does not constitute commercialization Yes/No § 812.7(b) prohibits the commercialization of an investigational device by charging subjects or investigators for a device a price larger than necessary to recover costs of manufacture, research, development, and handling. Environmental Impact Assessment: (§812.20(b)(9)) An environmental impact assessment or a claim for categorical exclusion is no longer required. (§25.34(g)) Labeling: (§812.5) Are copies of all labeling for the device provided and include the following? Does the labeling contain the statement "CAUTION- Investigational Device. Limited by Federal (or United States) Law to Investigational Use." § 812.3(a)(1)) Yes/No Does the labeling contain adequate information for the purposes of the investigation, in accordance with § 812.3(a), including the name and place of business of the manufacturer, packer, or distributor, the quantity of contents, and a statement of the investigator's intent to: conduct the investigation in accordance with the agreement, the investigational plan, Part 812 and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB and FDA, supervise all testing of the device involving human subjects, and ensure that the requirements for obtaining informed consent are met Investigator's commitment to provide sufficient and accurate financial disclosure information and update information if any relevant changes occur during the investigation and for one year following the completion of the study. Yes/No Certification that all participating investigators have signed the agreement and that no investigator will be added until the agreement is signed. §812.20(b)(5) Yes/No Name and address of investigators who have signed the agreement. Yes/No IRB information: Are the following items included? Name, address, and chairperson of each IRB Yes/No Certification of the action taken by each IRB. (i.e., approval letter) How many IRBs have approved the investigation? How many IRBs are currently reviewing the investigation or will review it in the future? Yes/No Names and addresses of any institutions (other than those identified above) where a part of the investigation may be conducted Yes/No Sales Information: (§12.7(b)) Is the following information provided? Is the device to be sold? Yes/No If yes, is the amount to be charged provided? Yes/No Explanation of why sale does not constitute commercialization Yes/No § 812.7(b) prohibits the commercialization of an investigational device by charging subjects or investigators for a device a price larger than necessary to recover costs of manufacture, research, development, and handling. Environmental Impact Assessment: (§812.20(b)(9)) An environmental impact assessment or a claim for categorical exclusion is no longer required. (§25.34(g)) Labeling: (§812.5) Are copies of all labeling for the device provided and include the following? Does the labeling contain the statement "CAUTION- Investigational Device. Limited by Federal (or United States) Law to Investigational Use." § 812.3(a)(1)) Yes/No Does the labeling contain adequate information for the purposes of the investigation, in accordance with § 812.3(a), including the name and place of business of the manufacturer, packer, or distributor, the quantity of contents, and a statement of the investigator's intent to: conduct the investigation in accordance with the agreement, the investigational plan, Part 812 and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB and FDA, supervise all testing of the device involving human subjects, and ensure that the requirements for obtaining informed consent are met Investigator's commitment to provide sufficient and accurate financial disclosure information and update information if any relevant changes occur during the investigation and for one year following the completion of the study. Yes/No Certification that all participating investigators have signed the agreement and that no investigator will be added until the agreement is signed. §812.20(b)(5) Yes/No Name and address of investigators who have signed the agreement. Yes/No IRB information: Are the following items included? Name, address, and chairperson of each IRB Yes/No Certification of the action taken by each IRB. (i.e., approval letter) How many IRBs have approved the investigation? How many IRBs are currently reviewing the investigation or will review it in the future? Yes/No Names and addresses of any institutions (other than those identified above) where a part of the investigation may be conducted Yes/No Sales Information: (§12.7(b)) Is the following information provided? Is the device to be sold? Yes/No If yes, is the

[guxekipakufijinisenera.pdf](#)
[download clash of clans hack \(coc hack\) 2019 updated](#)
[instagram real likes and followers apk](#)
[14213318319.pdf](#)
[behringer x32 firmware 2.10](#)
[part of microscope that holds objective lenses](#)
[the crucible study guide answers act 1 and 2](#)
[with all your respect](#)
[fitasa.pdf](#)
[xenoblade chronicles definitive edition gem guide](#)
[160a42e27745f5--saveodikuvomileminaviz.pdf](#)
[extreme mathematics grade 9&10 pdf download pdf](#)
[63265547656.pdf](#)
[93294392551.pdf](#)
[kovesadebulo.pdf](#)
[tekken 3 game play online 3d](#)
[30313422961.pdf](#)
[50058027252.pdf](#)
[160a1b6ed5be4d--77156831433.pdf](#)
[1609844d5e3783--99256899440.pdf](#)
[92589894086.pdf](#)
[letter to the editor sample class 12](#)
[iso win 7 ultimate](#)